{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T13:04:23Z","timestamp":1791464663632,"version":"4.3.4"},"reference-count":48,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Allogeneic hematopoietic cell transplantation (allo-HCT) can provide curative treatment for hematologic malignancies but is associated with prolonged lymphopenia that may contribute to an increased risk of infection and relapse, resulting in decreased survival. We hypothesized that patients with rapid and robust CD4 T- and B-cell recovery have improved survival and decreased treatment-related mortality (TRM). A total of 2089 patients were included who underwent first allo-HCT for acute myeloid leukemia\/acute lymphoblastic leukemia\/myelodysplastic syndrome from 2008 to 2019 reported to the Center for International Blood and Marrow Transplant Research with available CD4 counts at days 100 and 180. Patients (median age, 51 years [range, 2-75]) were categorized into 4 groups based on graft-versus-host disease (GVHD) prophylaxis: ex vivo T-cell depletion (TCD\/CD34), posttransplant cyclophosphamide, calcineurin inhibitor alone (CNI), or CNI with antithymocyte globulin. Based upon survival, we could identify optimal cutoff points for CD4+ T cells in pediatric (age of &amp;lt;20 years) patients: 248 \u00d7 106\/L and 420 \u00d7 106\/L at days 100 and 180, respectively; and in adult (age of &amp;gt;20 years) patients: 104 \u00d7 106\/L and 115 \u00d7 106\/L at days 100 and 180, respectively. In adults, day-100 CD4 count was associated with overall survival (OS), progression-free survival (PFS), and TRM but not relapse, incidence of infections, or chronic GVHD. Similarly, CD4 counts above the cutoff point at day 180 in adults were associated with improved OS, PFS, and TRM but no other outcomes. No clinical associations for CD4 counts were identifiable in pediatric patients. These findings underscore the importance of tailoring transplant strategies for adults to optimize immune recovery and improve patient outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015288","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T16:12:18Z","timestamp":1744992738000},"page":"3502-3517","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":5,"title":["Delayed T-cell recovery after hematopoietic cell transplantation is associated with decreased overall survival in adults"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5910-4571","authenticated-orcid":false,"given":"Miguel-Angel","family":"Perales","sequence":"first","affiliation":[{"name":"1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"},{"name":"2Department of Medicine, Weill Cornell Medical College, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcie","family":"Riches","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naya","family":"He","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3799-681X","authenticated-orcid":false,"given":"Michael J.","family":"Martens","sequence":"additional","affiliation":[{"name":"3Center for International Blood and Marrow Transplant Research, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI"},{"name":"4Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-3088","authenticated-orcid":false,"given":"Roy F.","family":"Chemaly","sequence":"additional","affiliation":[{"name":"5Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4001-9203","authenticated-orcid":false,"given":"Christopher E.","family":"Dandoy","sequence":"additional","affiliation":[{"name":"6Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Disease Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7665-7100","authenticated-orcid":false,"given":"Joshua A.","family":"Hill","sequence":"additional","affiliation":[{"name":"7Vaccine and Infectious Disease, Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"8Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5286-1329","authenticated-orcid":false,"given":"Miguel Angel","family":"Diaz","sequence":"additional","affiliation":[{"name":"9Department of Hematology\/Oncology, Hospital Infantil Universitario Ni\u00f1o Jesus, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8914-7927","authenticated-orcid":false,"given":"Shahrukh","family":"Hashmi","sequence":"additional","affiliation":[{"name":"10Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates"},{"name":"11Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN"},{"name":"12College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4175-5728","authenticated-orcid":false,"given":"Susan","family":"Prockop","sequence":"additional","affiliation":[{"name":"13Department of Hematopoietic Stem Cell Transplant, Dana-Farber Cancer Institute\/Boston Children's Center for Cancer and Blood Disorders, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1159-5607","authenticated-orcid":false,"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"14Department of Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer M.","family":"Beitinjaneh","sequence":"additional","affiliation":[{"name":"15Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard C.","family":"Hildebrandt","sequence":"additional","affiliation":[{"name":"16Division of Hematology and Medical Oncology, University of Missouri, Ellis Fischel Cancer Center, Columbia, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1515-2141","authenticated-orcid":false,"given":"Jeffery J.","family":"Auletta","sequence":"additional","affiliation":[{"name":"17Center for International Blood and Marrow Transplant Research, National Marrow Donor Program, Minneapolis, MN"},{"name":"18Division of Hematology\/Oncology\/Blood and Marrow Transplant and Division of Infectious Diseases, Nationwide Children\u2019s Hospital, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8561-4076","authenticated-orcid":false,"given":"Paul","family":"Szabolcs","sequence":"additional","affiliation":[{"name":"19Division of Blood and Marrow Transplantation and Cellular Therapies, UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA"},{"name":"20Department of Pediatrics and Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,10]]},"reference":[{"issue":"2","key":"2025072114012609200_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.V93.2.467","article-title":"Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions","volume":"93","author":"Small","year":"1999","journal-title":"Blood"},{"issue":"7","key":"2025072114012609200_bib10","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1097\/00007890-200204150-00026","article-title":"Factors influencing T-lymphopoiesis after allogeneic hematopoietic cell transplantation","volume":"73","author":"Storek","year":"2002","journal-title":"Transplantation"},{"issue":"8","key":"2025072114012609200_bib11","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1182\/blood-2002-05-1376","article-title":"Factors affecting antibody levels after allogeneic hematopoietic cell transplantation","volume":"101","author":"Storek","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2025072114012609200_bib12","first-page":"65","article-title":"Immune reconstitution following T-cell depleted bone marrow transplantation: effect of age and posttransplant graft rejection prophylaxis","volume":"3","author":"Small","year":"1997","journal-title":"Biol Blood Marrow Transpl"},{"issue":"13","key":"2025072114012609200_bib13","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1182\/blood-2007-06-093880","article-title":"T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin","volume":"110","author":"Jakubowski","year":"2007","journal-title":"Blood"},{"issue":"9","key":"2025072114012609200_bib14","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.bbmt.2011.01.005","article-title":"T cell-depleted unrelated donor stem cell transplantation provides favorable disease-free survival for adults with hematologic malignancies","volume":"17","author":"Jakubowski","year":"2011","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2025072114012609200_bib15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1038\/nm.3100","article-title":"Quantitative assessment of T cell repertoire recovery after hematopoietic stem cell transplantation","volume":"19","author":"van Heijst","year":"2013","journal-title":"Nat Med"},{"issue":"3","key":"2025072114012609200_bib2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1046\/j.1365-2141.2001.03135.x","article-title":"Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients","volume":"115","author":"Maury","year":"2001","journal-title":"Br J Haematol"},{"issue":"8552","key":"2025072114012609200_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0140-6736(87)90763-X","article-title":"Impact of T-cell depletion on outcome of allogeneic bone-marrow transplantation for standard-risk leukaemias","volume":"2","author":"Maraninchi","year":"1987","journal-title":"Lancet"},{"issue":"10","key":"2025072114012609200_bib4","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.bbmt.2007.07.005","article-title":"Absolute lymphocyte count on day 30 is a surrogate for robust hematopoietic recovery and strongly predicts outcome after T cell-depleted allogeneic stem cell transplantation","volume":"13","author":"Savani","year":"2007","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2025072114012609200_bib5","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood.V91.9.3481","article-title":"Identification of patients who may benefit from prophylactic immunotherapy after bone marrow transplantation for acute myeloid leukemia on the basis of lymphocyte recovery early after transplantation","volume":"91","author":"Powles","year":"1998","journal-title":"Blood"},{"issue":"2","key":"2025072114012609200_bib6","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2141.2004.04891.x","article-title":"Clinical impact of early absolute lymphocyte count after allogeneic stem cell transplantation","volume":"125","author":"Kim","year":"2004","journal-title":"Br J Haematol"},{"issue":"1","key":"2025072114012609200_bib7","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.bmt.1704082","article-title":"Early lymphocyte recovery is an important determinant of outcome following allogeneic transplantation with CD34+ selected graft and limited T-cell addback","volume":"32","author":"Chakrabarti","year":"2003","journal-title":"Bone Marrow Transpl"},{"issue":"8","key":"2025072114012609200_bib8","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1080\/10428194.2016.1265113","article-title":"Early recovery of T-cell function predicts improved survival after T-cell depleted allogeneic transplant","volume":"58","author":"Goldberg","year":"2017","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"2025072114012609200_bib9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/(SICI)1096-8652(199702)54:2<131::AID-AJH6>3.0.CO;2-Y","article-title":"Infectious morbidity in long-term survivors of allogeneic marrow transplantation is associated with low CD4 T cell counts","volume":"54","author":"Storek","year":"1997","journal-title":"Am J Hematol"},{"issue":"12","key":"2025072114012609200_bib16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1038\/sj.bmt.1705381","article-title":"Rapid helper T-cell recovery above 200 x 10 6\/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation","volume":"37","author":"Kim","year":"2006","journal-title":"Bone Marrow Transpl"},{"issue":"1","key":"2025072114012609200_bib17","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/sj.bmt.1705870","article-title":"Lymphocyte subsets recovery following allogeneic bone marrow transplantation (BMT): CD4+ cell count and transplant-related mortality","volume":"41","author":"Berger","year":"2008","journal-title":"Bone Marrow Transpl"},{"issue":"11","key":"2025072114012609200_bib18","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/j.bbmt.2012.06.005","article-title":"Immune recovery in adult patients after myeloablative dual umbilical cord blood, matched sibling, and matched unrelated donor hematopoietic cell transplantation","volume":"18","author":"Kanda","year":"2012","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2025072114012609200_bib19","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2141.1986.tb07580.x","article-title":"Recovery of immunoglobulin isotypes following T-cell depleted allogeneic bone marrow transplantation","volume":"64","author":"Brenner","year":"1986","journal-title":"Br J Haematol"},{"issue":"3","key":"2025072114012609200_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/BF00320027","article-title":"Serum immunoglobulin levels following allogeneic bone marrow transplantation","volume":"51","author":"Perreault","year":"1985","journal-title":"Blut"},{"issue":"3","key":"2025072114012609200_bib21","doi-asserted-by":"crossref","first-page":"815","DOI":"10.4049\/jimmunol.141.3.815","article-title":"Acquisition of Ig isotype diversity after bone marrow transplantation in adults. A recapitulation of normal B cell ontogeny","volume":"141","author":"Velardi","year":"1988","journal-title":"J Immunol"},{"issue":"5","key":"2025072114012609200_bib22","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/00007890-198405000-00007","article-title":"Immunologic recovery in human marrow graft recipients given cyclosporine or methotrexate for the prevention of graft-versus-host disease","volume":"37","author":"Witherspoon","year":"1984","journal-title":"Transplantation"},{"issue":"8","key":"2025072114012609200_bib23","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ibd\/izad024","article-title":"The underappreciated role of secretory IgA in IBD","volume":"29","author":"Bamias","year":"2023","journal-title":"Inflamm Bowel Dis"},{"issue":"1","key":"2025072114012609200_bib24","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41385-019-0227-4","article-title":"IgA and the intestinal microbiota: the importance of being specific","volume":"13","author":"Pabst","year":"2020","journal-title":"Mucosal Immunol"},{"issue":"3","key":"2025072114012609200_bib25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007890-199009000-00012","article-title":"Development of IgA deficiency after bone marrow transplantation. The influence of acute and chronic graft-versus-host disease [published correction appears in Transplantation. 1991;51(1):285]","volume":"50","author":"Abedi","year":"1990","journal-title":"Transplantation"},{"issue":"5","key":"2025072114012609200_bib26","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-3083.1987.tb02280.x","article-title":"Polyclonal antibody secretion during acute graft-versus-host disease","volume":"26","author":"Ringd\u00e9n","year":"1987","journal-title":"Scand J Immunol"},{"issue":"6","key":"2025072114012609200_bib27","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2025072114012609200_bib28","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 diagnosis and staging working group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transpl"},{"issue":"5","key":"2025072114012609200_bib29","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol"},{"issue":"6","key":"2025072114012609200_bib30","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.jaci.2016.12.992","article-title":"Viral reactivations and associated outcomes in the context of immune reconstitution after pediatric hematopoietic cell transplantation","volume":"140","author":"Admiraal","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"2025072114012609200_bib31","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1182\/blood.2020007905","article-title":"CD4+ T-cell reconstitution predicts survival outcomes after acute graft-versus-host-disease: a dual-center validation","volume":"137","author":"de Koning","year":"2021","journal-title":"Blood"},{"issue":"9","key":"2025072114012609200_bib32","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.jcyt.2023.05.012","article-title":"Early immune reconstitution as predictor for outcomes after allogeneic hematopoietic cell transplant; a tri-institutional analysis","volume":"25","author":"Troullioud Lucas","year":"2023","journal-title":"Cytotherapy"},{"issue":"2","key":"2025072114012609200_bib33","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1182\/bloodadvances.2019001021","article-title":"Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation","volume":"4","author":"Ando","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"2025072114012609200_bib34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1182\/blood.2021013054","article-title":"Signatures of GVHD and relapse after posttransplant cyclophosphamide revealed by immune profiling and machine learning","volume":"139","author":"McCurdy","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2025072114012609200_bib35","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1038\/s41409-022-01666-x","article-title":"Impact of anti-T-lymphocyte globulin dosing on GVHD and immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation","volume":"57","author":"Massoud","year":"2022","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2025072114012609200_bib36","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41409-024-02474-1","article-title":"Immunological reconstitution and infections after alloHCT - a comparison between post-transplantation cyclophosphamide, ATLG and non-ATLG based GvHD prophylaxis","volume":"60","author":"Meyer","year":"2024","journal-title":"Bone Marrow Transpl"},{"issue":"19","key":"2025072114012609200_bib37","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMc1601364","article-title":"Antilymphocyte globulin for chronic graft-versus-host disease","volume":"374","author":"Kr\u00f6ger","year":"2016","journal-title":"N Engl J Med"},{"issue":"36","key":"2025072114012609200_bib38","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.1200\/JCO.2017.75.8177","article-title":"Prospective, randomized, double-blind, phase III clinical trial of anti-T-lymphocyte globulin to assess impact on chronic graft-versus-host disease-free survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation","volume":"35","author":"Soiffer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"4","key":"2025072114012609200_bib39","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"2025072114012609200_bib40","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"2","key":"2025072114012609200_bib41","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1016\/j.jtct.2023.12.083","article-title":"Calcineurin inhibitor-free graft-versus-host disease (GVHD) prophylaxis in hematopoietic cell transplantation (HCT) with myeloablative conditioning regimens (MAC) and HLA-matched donors: long term follow up of BMT CTN 1301 progress II trial","volume":"30","author":"Pasquini","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"8","key":"2025072114012609200_bib42","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.bbmt.2019.02.021","article-title":"Standard antithymocyte globulin dosing results in poorer outcomes in overexposed patients after ex vivo CD34(+) selected allogeneic hematopoietic cell transplantation","volume":"25","author":"Scordo","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"3","key":"2025072114012609200_bib43","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1182\/bloodadvances.2021005584","article-title":"Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation","volume":"6","author":"Lakkaraja","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2025072114012609200_bib44","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.bbmt.2018.12.065","article-title":"Rabbit antithymocyte globulin serum levels: factors impacting the levels and clinical outcomes impacted by the levels","volume":"25","author":"Jamani","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"1","key":"2025072114012609200_bib45","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/bjh.17563","article-title":"Incidence and impact of community respiratory viral infections in post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis and haploidentical stem cell transplantation","volume":"194","author":"Mulroney","year":"2021","journal-title":"Br J Haematol"},{"issue":"23","key":"2025072114012609200_bib46","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1182\/blood.2020009362","article-title":"Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis","volume":"137","author":"Goldsmith","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2025072114012609200_bib47","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"2025072114012609200_bib48","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/bloodadvances.2022008545","article-title":"Abatacept GVHD prophylaxis in unrelated hematopoietic cell transplantation for pediatric bone marrow failure","volume":"7","author":"Stenger","year":"2023","journal-title":"Blood Adv"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3502\/2402334\/blooda_adv-2024-015288-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3502\/2402334\/blooda_adv-2024-015288-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T18:01:39Z","timestamp":1753120899000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/14\/3502\/536809\/Delayed-T-cell-recovery-after-hematopoietic-cell"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,10]]},"references-count":48,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015288","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,22]]},"published":{"date-parts":[[2025,7,10]]}}}